N
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES
NASDAQ: NAMS (NewAmsterdam Pharma Company N.V)
最近更新时间: 6小时之前21.50
1.03 (5.03%)
| 前收盘价格 | 20.47 |
| 收盘价格 | 20.57 |
| 成交量 | 1,075,468 |
| 平均成交量 (3个月) | 1,400,846 |
| 市值 | 2,513,435,392 |
| 预期市盈率 (P/E Forward) | 119.05 |
| 价格/销量 (P/S) | 385.46 |
| 股市价格/股市净资产 (P/B) | 4.29 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业利益率 (TTM) | -2,314.47% |
| 稀释每股收益 (EPS TTM) | -1.84 |
| 季度收入增长率 (YOY) | 112.60% |
| 总债务/股东权益 (D/E MRQ) | 0.05% |
| 流动比率 (MRQ) | 19.98 |
| 营业现金流 (OCF TTM) | -140.43 M |
| 杠杆自由现金流 (LFCF TTM) | -99.00 M |
| 资产报酬率 (ROA TTM) | -18.15% |
| 股东权益报酬率 (ROE TTM) | -31.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | NewAmsterdam Pharma Company N.V | 混合的 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | 0.83 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 0.39% |
| 机构持股比例 | 111.32% |
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合